Esperion Therapeutics | ESPR - Des Atouts

Prix De L'Action
2.64
Variation Quotidienne
0.09 3.33%
Mensuellement
-20.15%
Annuel
51.44%
Q1 Prévisions
2.47




Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Alterity Therapeutics Limited AUD 27.32M 6.07M 2023-06
Amarin USD 670.78M 10.96M 2025-12
Amgen USD 90.59B 445M 2025-12
Biogen USD 29.44B 232M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Cipla INR 401.64B 27.77B 2025-09
CSL USD 37.9B 1.5B 2025-12
Cytokinetics USD 1.42B 12.02M 2025-12
Daiichi Sankyo JPY 3.82T 252.52B 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Geron USD 570.54M 3.16M 2025-12
Grifols EUR 23.15B 142.7M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
Merck USD 129.55B 12.02B 2025-09
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Moderna USD 12.34B 203M 2025-12
Nektar Therapeutics USD 301.35M 93.81M 2025-09
Pfizer USD 208.73B 2.64B 2025-09
PTC Therapeutics USD 2.9B 255.07M 2025-12
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Sanofi EUR 126.81B 2.99B 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
United Therapeutics USD 7.88B 528.9M 2025-12
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12